- Company
- Sales in the PPI market are↑ 60% over the past 3 years
- by Kim, Jin-Gu Feb 10, 2022 05:53am
- The PPI anti- ulcer drug market has changed rapidly since the Ranitidine crisis. The market expanded sharply shortly after Ranitidine crisis, but growth has slowed down in the past year. Esomeprazole, Rabeprazole, and Ilaprazole enjoyed the reflective effect of Ranitidine crisis. On the other hand, in the case of Lansoprazole and Pantoprazole
- Company
- Opdivo to be deliberated by CDDC for stomach cancer indicati
- by Eo, Yun-Ho Feb 9, 2022 06:10am
- Whether a reimbursed treatment option would become available in the field of gastric cancer is receiving attention. According to industry sources, Ono and BMS’s PD-1 inhibitor immuno-oncology drug ‘Opdivo (nivolumab)’ will be deliberated by the National Health Insurance Service’s Cancer Disease Deliberation Committee on the 23rd of
- Policy
- Following Kymriah, Zolgensma is also about to be reviewed
- by Lee, Tak-Sun Feb 9, 2022 06:09am
- So-called "one-shot treatments" that treat specific rare diseases with one administration are speeding up the reimbursement. Following Kymriah, which treats blood cancer such as leukemia and lymphoma, Zolgensma (Onasemnogene Abeparvovec), which treats a rare disease called SMA, is also set to be reviewed by HIRA's Drug Reimbursement Evaluati
- Policy
- Novavax vaccine passed the national lot release procedure
- by Lee, Hye-Kyung Feb 9, 2022 06:09am
- 840,000 doses of Nuvaxovid PFS, a Novavax vaccine, have been released in the national lot. The MFDS (Minister Kim Kang-rip) announced on the 8th that SK Bioscience has approved 840,000 Nuvaxovid PFS manufactured in Korea for the first time. Nuvaxovid PFS, which was approved for shipment to the country this time, is a vaccine manufactured
- Company
- Famotidine market triples 2 years after ranitidine issue
- by Chon, Seung-Hyun Feb 9, 2022 06:09am
- The H2 receptor antagonist market had fluctuated with the ban of the ranitidine ingredient in antiulcer drugs. The gap made by the exit of ranitidine initially shrunk the market into nearly half its size. Famotidine enjoyed the most reflective benefits with its market size increasing nearly threefold after the ranitidine impurity issue. Also, ni
- Company
- Can the Antigen Rapid Test be widely used?
- by Choi-sun Feb 9, 2022 06:09am
- Although they are concerned about the transition to the COVID-19 test system, which adds the Antigen Rapid Test to the current PCR test, opinions are divided as they argue that this is only a concern. Unlike the initial virus that occurred in Wuhan two years ago, mutant viruses such as Omikron have a lot of detection in the body, so the Antigen
- Policy
- Focus on the possibility of NovaVax vaccine booster shot
- by Lee, Tak-Sun Feb 8, 2022 05:55am
- Experts expressed great interest in the cross-vaccination use of the vaccine during the Novavax COVID-19 vaccine screening process approved in Korea on the 12th of last month. This is because Novavax is likely to be used for additional vaccinations, so-called booster shots, in a situation where most people have been vaccinated with different
- Company
- EUSA Pharma establishes subsidary in Korea
- by Eo, Yun-Ho Feb 8, 2022 05:55am
- The UK-based pharmaceutical company EUSA Pharma is entering the Korean market. According to industry sources, EUSA Pharma established the Asia Pacific Regional Headquarters in Korea and launched its Korean subsidiary, EUSA Pharma Korea. EUSA Pharma is a global specialty pharmaceutical company that focuses on rare and incurable diseases
- Product
- Defective tablets of Lipitor were found
- by Kim JiEun Feb 8, 2022 05:54am
- Defective drugs have been found one after another in Lipitor, one of the most frequent prescription drugs, requiring caution when preparing. According to a pharmacist in Seoul on the 3rd, a defective tablet was recently found in a bottle of Lipitor again following November last year. The pharmacist said he found a suspicious substance wh
- Company
- Entresto's outpatient prescriptions exceed ₩30 billion
- by Feb 8, 2022 05:54am
- Sales of Novartis’ chronic heart failure treatment ‘Entresto’ exceeded &8361;30 billion only 5 years into its release. In the midst of drug price cuts and domestic patent challenges, Entresto is seeking greater growth this year by expanding the scope of indications and reimbursement benefits. According to the market research instituti
